2024
Progesterone receptor status predicts aggressiveness of human endometriotic lesions in murine avatars
Flores V, Sahin C, Taylor H. Progesterone receptor status predicts aggressiveness of human endometriotic lesions in murine avatars. F&S Science 2024, 6: 65-72. PMID: 39393571, DOI: 10.1016/j.xfss.2024.10.004.Peer-Reviewed Original ResearchProgestin-based therapyAggressive forms of endometriosisPR lesionsProgesterone receptorGnRH antagonistMedroxyprogesterone acetatePR statusEndometriotic lesionsAggressive formResponse to MPAResponse to medical therapyPost-treatment sizeProgesterone receptor statusHuman endometriotic lesionsResponse to progestinsChronic gynecological diseaseDaily subcutaneous injectionsReproductive-age womenMouse xenograft modelResponse to medicationEndometrioma lesionsReceptor statusHormone suppressionPR expressionClinical response
2023
The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas
Moreira-Dinzey J, Zhan H, Rozenblit M, Krishnamurti U, Harigopal M, Zhong M, Liang Y. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas. Human Pathology 2023, 137: 56-62. PMID: 37127079, DOI: 10.1016/j.humpath.2023.04.017.Peer-Reviewed Original ResearchConceptsMetastatic tumorsBreast carcinomaGenetic aberrationsPR statusPrimary tumorBreast cancerControl groupER/PR statusEstrogen receptor-positive breast carcinomasER-positive breast cancerER positivity rateMetastatic breast cancerProgesterone receptor statusMetastatic breast carcinomaMore liver metastasesPrimary breast carcinomaWild-type groupEstrogen receptor 1 geneReceptor 1 geneWild-type controlsLiver metastasesReceptor statusClinicopathological featuresER expressionControl tumors
2022
Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis
Hercules SM, Alnajar M, Chen C, Mladjenovic SM, Shipeolu BA, Perkovic O, Pond GR, Mbuagbaw L, Blenman KR, Daniel JM. Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis. BMJ Open 2022, 12: e055735. PMID: 35623750, PMCID: PMC9150263, DOI: 10.1136/bmjopen-2021-055735.Peer-Reviewed Original ResearchConceptsTNBC frequencySystematic reviewReceptor statusAggressive triple-negative breast cancer subtypeTriple-negative breast cancer subtypeER/PR statusASCO/CAP guidelinesBreast cancer tissue samplesCertainty of evidenceInverse variance methodRisk of biasBreast cancer prevalenceBreast cancer subtypesAfrican Journals OnlineCancer tissue samplesWeb of ScienceRecommendations AssessmentGRADE approachPR statusCAP guidelinesEligible participantsSELECTING STUDIESHER2 statusCancer prevalenceModified assessment tool
2018
Progesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis
Flores VA, Vanhie A, Dang T, Taylor HS. Progesterone Receptor Status Predicts Response to Progestin Therapy in Endometriosis. The Journal Of Clinical Endocrinology & Metabolism 2018, 103: 4561-4568. PMID: 30357380, PMCID: PMC6226602, DOI: 10.1210/jc.2018-01227.Peer-Reviewed Original ResearchConceptsProgestin-based therapyPR statusReceptor statusEndometriotic lesionsPredictive valueEndometriosis-associated painProgesterone receptor levelsRetrospective cohort studyFirst-line treatmentProgesterone receptor statusNegative predictive valuePositive predictive valueElectronic medical recordsRabbit polyclonal IgGPrecision-based approachesProgestin therapyHormonal therapyEndometriosis treatmentCohort studyPredictive markerMedical recordsReceptor levelsH-scoreAcademic centersEndometriosis
2013
Prevalence of germline TP53 mutations in HER2+ breast cancer patients
Rath MG, Masciari S, Gelman R, Miron A, Miron P, Foley K, Richardson AL, Krop IE, Verselis SJ, Dillon DA, Garber JE. Prevalence of germline TP53 mutations in HER2+ breast cancer patients. Breast Cancer Research And Treatment 2013, 139: 193-198. PMID: 23580068, PMCID: PMC4280061, DOI: 10.1007/s10549-012-2375-z.Peer-Reviewed Original ResearchConceptsGermline TP53 mutationsLi-Fraumeni syndromeBreast cancer ageBreast cancerTP53 mutationsCancer ageER/PR statusYoung womenGermline TP53 mutation carriersGermline TP53 testingUnselected young womenTP53 mutation carriersBreast cancer patientsCohort of womenFamily cancer historyPotential clinical impactTP53 carriersTP53 testingPR statusSingle centerFrequent tumorsCancer historyCancer patientsChompret criteriaMultiplex ligation-dependent probe amplification (MLPA) technique
2011
P3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast.
Sowden M, Flynn C, Bossuyt V, Lannin D, Chagpar A. P3-05-08: Hormone Receptor Heterogeneity in Ductal Intraepithelial Neoplasia (Ductal Carcinoma In Situ) of the Breast. Cancer Research 2011, 71: p3-05-08-p3-05-08. DOI: 10.1158/0008-5472.sabcs11-p3-05-08.Peer-Reviewed Original ResearchDuctal intraepithelial neoplasiaHormone receptor statusReceptor statusNuclear gradeIntraepithelial neoplasiaSame tumorHormonal therapyDifferent nuclear gradesHospital tumor registryMedian patient ageMajority of patientsLobular intraepithelial neoplasiaDin-2DIN 1Cohort of interestDIN patientsPR positivityPatient ageER statusPR statusTumor RegistrySingle pathologistInvasive tumorsSame patientPatientsCharacteristics of multifocal and multicentric breast cancers detetected by preoperative MRI.
Killelea B, Grube B, Philpotts L, Sowden M, Horowitz N, Lannin D. Characteristics of multifocal and multicentric breast cancers detetected by preoperative MRI. Journal Of Clinical Oncology 2011, 29: 67-67. DOI: 10.1200/jco.2011.29.27_suppl.67.Peer-Reviewed Original ResearchBreast cancer patientsSecond tumorPreoperative MRISecond malignanciesPR statusCancer patientsBreast cancerER/PR statusMulticentric breast cancerSuspicious MRI findingsNumber of patientsDiagnosis of cancerLobular histologyNodal statusContralateral breastMRI findingsNode positiveTumor characteristicsTumor sizeHER2 statusAdditional tumorsSecondary lesionsSecondary tumorsPatientsControl groupEffect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases
Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M. Effect of Tumor Subtype on Survival and the Graded Prognostic Assessment for Patients With Breast Cancer and Brain Metastases. International Journal Of Radiation Oncology • Biology • Physics 2011, 82: 2111-2117. PMID: 21497451, PMCID: PMC3172400, DOI: 10.1016/j.ijrobp.2011.02.027.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overBrain NeoplasmsBreast NeoplasmsBreast Neoplasms, MaleCohort StudiesFemaleHumansKarnofsky Performance StatusMaleMiddle AgedMultivariate AnalysisPrognosisProportional Hazards ModelsReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRetrospective StudiesConceptsGraded Prognostic AssessmentER/PRKarnofsky performance statusMultivariate Cox regressionBrain metastasesBreast-GPATumor subtypesPrognostic factorsCox regressionBreast cancerPrognostic assessmentDiagnosis-Specific Graded Prognostic AssessmentMulti-institutional retrospective databaseER/PR statusHER2-positive patientsHER2-negative patientsSignificant prognostic factorsSubgroup of patientsBreast cancer patientsClinical decision makingLog-rank statisticsKPS 60Performance statusPR statusCancer patients
2009
Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
Caudle A, Gonzalez-Angulo A, Kelly H, Liu P, Pusztai L, Symmans W, Kuerer H, Mittendorf E, Hortobagyi G, Meric-Bernstam F. Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2009, 27: 603-603. DOI: 10.1200/jco.2009.27.15_suppl.603.Peer-Reviewed Original ResearchNeoadjuvant chemotherapyHigh Ki-67High tumor gradeStable diseasePR statusBreast cancerTumor gradeKi-67Negative ERNegative ER/PR statusFirst-line surgical approachSingle comprehensive cancer centerTumor progressionER/PR statusTaxane-based regimensComplete pathologic responseSubset of patientsLymph node metastasisHigher T stageComprehensive cancer centerPre-treatment characteristicsNCT regimenLymphovascular invasionMost patientsPathologic response
2008
Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome
Harigopal M, Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome. Breast Cancer Research And Treatment 2008, 115: 77-85. PMID: 18521745, DOI: 10.1007/s10549-008-0063-9.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAutomationBiomarkers, TumorBreast NeoplasmsFemaleGene Expression Regulation, NeoplasticHumansMultivariate AnalysisNuclear Receptor Coactivator 3Oligonucleotide Array Sequence AnalysisPrognosisProportional Hazards ModelsReceptors, EstrogenReceptors, ProgesteroneRegression AnalysisTranscription FactorsTreatment OutcomeConceptsHigh AIB1 expressionTranscription intermediary factor 2Poor patient outcomesAIB1 expressionTissue microarrayPatient outcomesHER2/neu statusBreast cancer tissue microarrayFluorescent immunohistochemical stainingWorse overall survivalUnivariate survival analysisBreast cancer specimensCancer tissue microarrayHER2/neuCoregulatory proteinsCox univariate survival analysesBreast tissue microarraysOverall survivalER statusPR statusPrognostic significanceIndependent associationBreast cancerPrognostic biomarkerImmunohistochemical stainingSpecific Genes Expressed in Association with Progesterone Receptors in Meningioma
Claus EB, Park PJ, Carroll R, Chan J, Black PM. Specific Genes Expressed in Association with Progesterone Receptors in Meningioma. Cancer Research 2008, 68: 314-322. PMID: 18172325, PMCID: PMC3256746, DOI: 10.1158/0008-5472.can-07-1796.Peer-Reviewed Original ResearchConceptsHormone receptor statusPR statusReceptor statusER statusGene expressionMean ageNeurosurgical resectionProgesterone receptorWomen's HospitalClinical markersSurgical specimensExtracellular matrix pathwaysEstrogen hormone receptorsMeningioma casesMeningioma patientsGene expression profiling resultsGrade 1MeningiomasHormone receptorsNeurofibromatosis type 2 geneStrong associationType 2 geneExpression profiling resultsGenetic subgroupsExpression of genes
2007
Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis
Sherman ME, Rimm DL, Yang XR, Chatterjee N, Brinton LA, Lissowska J, Peplonska B, Szeszenia‐Dąbrowska N, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, Kalaylioglu Z, Harigopal M, Charrette L, Falk RT, Richesson D, Anderson WF, Hewitt SM, García‐Closas M. Variation in breast cancer hormone receptor and HER2 levels by etiologic factors: A population‐based analysis. International Journal Of Cancer 2007, 121: 1079-1085. PMID: 17487843, DOI: 10.1002/ijc.22812.Peer-Reviewed Original ResearchConceptsBody mass indexPostmenopausal womenEtiologic factorsHER2 levelsPremenopausal womenOdds ratioER alphaBreast cancer hormone receptor statusPopulation-based case-control studyBreast Cancer Hormone ReceptorsHormone receptor statusCase-control studyPopulation-based analysisPathologic characteristicsPR statusReceptor statusMass indexER betaClinical recordsMarker levelsHER2 expressionLarge tumorsBreast cancerReceptor levelsTumor features
2004
Molecular markers for prognosis after isolated postmastectomy chest wall recurrence
Haffty BG, Hauser A, Choi DH, Parisot N, Rimm D, King B, Carter D. Molecular markers for prognosis after isolated postmastectomy chest wall recurrence. Cancer 2004, 100: 252-263. PMID: 14716758, DOI: 10.1002/cncr.11915.Peer-Reviewed Original ResearchConceptsHER-2/neu statusChest wall recurrencePositive HER-2/neu statusLocal-regional controlLocal recurrenceNeu statusDistant metastasisPR statusProgesterone receptorBreast carcinomaDistant metastasis-free survival ratesLocal chest wall recurrenceDistant metastasis-free rateMetastasis-free survival ratesHER-2/neuLymph node recurrencePositive PR statusProgression-free rateSimultaneous distant metastasesOperable breast carcinomaLocal-regional recurrenceMetastasis-free ratePostmastectomy chest wallExternal beam radiotherapyLong-term survival
1993
A hospital-based case-control study of breast-cancer risk factors by estrogen and progesterone receptor status
Yoo K, Tajima K, Miura S, Yoshida M, Murai H, Kuroishi T, Lee Y, Risch H, Dubrow R. A hospital-based case-control study of breast-cancer risk factors by estrogen and progesterone receptor status. Cancer Causes & Control 1993, 4: 39-44. PMID: 8431529, DOI: 10.1007/bf00051712.Peer-Reviewed Original ResearchConceptsHospital-based case-control studyBreast cancer risk factorsProgesterone receptor statusCase-control studyEstrogen receptorRisk factorsBreast cancerPR statusReceptor statusPR-negative breast cancerER-negative breast cancerFull-term pregnancyPR-negative casesBreast cancer casesCancer-free controlsSignificant differencesER statusMenstrual regularityEtiologic distinctionsBorderline differenceNegative casesCancerStatusAgePercent
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply